ETON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ETON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eton Pharmaceuticals has the GF Value Rank of 8.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's GF Value Rank distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's GF Value Rank falls into.
Thank you for viewing the detailed overview of Eton Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
David Krempa | officer: Chief Business Officer | 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Sean Brynjelsen | director, officer: President & CEO | C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010 |
James R. Gruber | officer: Chief Financial Officer | 618 AMES STREET, LIBERTYVILLE IL 60048 |
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
William Wilson Troutman | officer: CFO, Treasurer & Secretary | 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Imprimis Pharmaceuticals, Inc. | 10 percent owner | 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215 |
Jennifer Mckie Adams | director | 5410 TENNESSEE AVE, NASHVILLE TN 37209 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Mark L Baum | director | C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130 |
Paul V Maier | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-03-2022
By Value_Insider Value_Insider • 11-02-2022
By Ds*** Ds*** • 08-30-2022
By PRNewswire • 07-12-2023
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 07-19-2023
By Stock market mentor Stock market mentor • 01-11-2023
By Marketwired • 10-30-2023
By GuruFocusNews GuruFocusNews • 12-20-2021
By GuruFocusNews GuruFocusNews • 04-11-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.